Head-To-Head Comparison OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN - Cardiovascular And Safety Events

Other Key Studies

• SGLT2 INHIBITORS AND PARKINSON’S DISEASE (PD) RISK IN OLDER POPULATIONS WITH TYPE 2 DIABETES (T2D)

Compared to DPP4 inhibitors, SGLT2 inhibitors were associated with a significantly lower risk of indecent PD in people with T2D.

• CARDIOVASCULAR AND MORTALITY OUTCOMES WITH SGLT2 INHIBITORS IN PATIENTS WITH ATRIAL FIBRILLATION AND TYPE 2 DIABETES

In a nationwide cohort of patients with T2DM and AF, SGLT2 inhibitors showed a lower risk of mortality compared to DPP4 inhibitors. This may support the use of SGLT2 inhibitors as the first-line anti-diabetic medication in patients with T2DM and AF to prevent adverse outcomes.

• EFFICACY AND SAFETY OF SGLT2i VS. OTHER ORAL ANTIDIABETIC DRUGS AS DUAL THERAPY ADD-ON TO METFORMIN IN TYPE 2 DIABETES

Compared with other OADs + met dual therapies, SGLT-2i + met exhibited noninferior efficacy and significantly reduced risk of hypoglycaemia while risks of MI and UTI were not significantly different. Results from this study reinforce the recommendation of dual therapy in international guidelines, depending on patients’ treatment goals and risk profiles.

• A CORRELATIONAL STUDY ON IMPROVING PATIENTS’ COGNITION OF DIABETES AND LONG-TERM REVERSAL OF DIABETES

Improvement in cognitive behavior among patients with type 2 diabetes is associated with increased long-term diabetes reversal rates, increased muscle mass, and decreased body fat rates.

• DIFFERENT EFFECTS OF OCCUPATION AND LEISURE-TIME PHYSICAL ACTIVITY ON LONG-TERM GLUCOSE VARIABILITY IN TYPE 2 DIABETES

LTPA and OPA might have different effects in long-term glycemic variability in patients with type 2 diabetes.

• SOCIAL DETERMINANTS OF HEALTH AND EARLY-ONSETTYPE 2 DIABETES—A QUALITATIVE STUDY

SoDH play a significant role in early screening, diagnosis and care possibly influencing diabetes remission. Peer norms and familial risk affect diabetes perception in this population. Emphasizing weight loss or a healthy lifestyle may unintentionally deepen the stigma by reinforcing feelings of self-blame.

• ROLE OF CARDIOVASCULAR RISK COMMUNICATION IN MOTIVATING SELF-MANAGEMENT OF YOUNG-ONSET TYPE 2 DIABETES (YOD)—A MIXED-METHODS STUDY

Cardiovascular risk communication, especially using lifetime risk predictions, may play an important role in interventions to motivate YOD self-management.

• RISK FACTORS FOR COMBINED SEVERE DIABETIC COMPLICATIONS (CSDC) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

The risk of CSDC decreased as the number of achieved targets for atherosclerotic risk factors increased, suggesting that multifactorial interventions are necessary to prevent these conditions.

• THE CORONARY FLOW RESERVE INCREASE AFTER DAPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES IS MAINTAINED AFTER FOUR YEARS—A FOUR-YEAR DAPAHEART FOLLOW-UP STUDY

This 4-years follow-up trial demonstrates that the 30% increase of CFR obtainedfter 4 weeks treatment is maintained after 4 years, confirming the previous published results in a new population. This improvement in CFR may have important implications on the management and prognosis of patients with T2D and CAD.

• EFFICACY AND SAFETY OF SODIUM–GLUCOSE COTRANSPORTER 2 INHIBITORS (SGLT2i) VS. DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4i) AS INITIATOR THERAPY WITH TYPE 2 DIABETES ON CARDIOVASCULAR OUTCOMES—A SYSTEMATIC REVIEW AND META-ANALYSIS

Findings suggest that compared to DPP4is, initiating treatment with SGLT2is provides cardiovascular disease protection and can be considered for use in patients with type 2 diabetes.

• GLYCEMIC VARIABILITY AFTER INITIATION OF SGLT2 INHIBITORS IN CKD

After SGLT2i initiation in CKD, while mean glycemia and TIR remained unchanged, glycemic variability diminished. This finding warrants further investigation in a larger study.

• PRESCRIPTION PATTERN OF SGLT-2 INHIBITORS AMONG SENIORS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE IN A PRIMARY CARE SETTING

In a primary care clinic, SGLT2i were prescribed in 40.7% of seniors with T2DM and CKD but were commonly used among patients with cardiovascular diseases and those requiring insulin. Further investigation is needed to understand this gap in knowledge and formulate a mitigation strategy to expand SGLT2i use in eligible patients.

• IMPAIRED KIDNEY FUNCTION IN DIABETIC PATIENTS — A WARNING

  Among the patients who got themselves tested, there is a significant proportion of patients who don’t fall within the prescribed limits. These numbers would have been significantly higher than now if there had been no gap between expectations and reality. Hence, regular screening is important to prevent future complications.

• A NONINVASIVE INDEX FOR SIGNIFICANT LIVER FIBROSIS AND STRATIFYING RISK OF CIRRHOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PRIMARY CARE

  The non-invasive ADD index can be applied to screen significant fibrosis and cirrhosis in patients with T2DM in primary care

• RENAL HYPERMETABOLISM IN YOUTH-ONSET TYPE 2 DIABETES (T2D)—A C-11 ACETATE PET SCAN ANALYSIS

  The study demonstrates a pronounced elevation in oxidative metabolism and a notable mismatch between oxidative metabolism and perfusion in youths with obesity and T2D, compared to NWC. This is associated with increased albuminuria. These findings corroborate the transcriptional changes observed in kidney biopsies, particularly in the transcripts of TCA and oxidative phosphorylation, underscoring the functional relevance of these molecular alterations.

• THE TRIGLYCERIDE-GLUCOSE INDEX AND THE PRESENCE OF CORONARY ARTERY DISEASE ARE MUTUALLY INDEPENDENT PREDICTORS FOR THE DEVELOPMENT OF TYPE 2 DIABETES MELLITUS

  TyG-Index and the presence of CAD are mutually independent predictors for the development of T2DM

• PREVENTION OF SEVERE LOWER EXTREMITY ARTERY DISEASE IN PATIENTS WITH DIABETES—ANALYSIS OF FACTORS USING A LARGE DATABASE

  In addition to the implementation of educational hospitalization, this study will help in the selection of drugs to reduce the severity of LEAD.

Source : ADA 84th Scientific Session